Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Sarcoma, Kaposi 1AIDS-related Kaposi sarcoma 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2385Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1833Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1017Vincristine 964Cetuximab 945Trastuzumab 945Prednisone 942Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
halofuginone × Clear all
NCT00064142 2013-06-05

Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma

National Cancer Institute (NCI)

Phase 2 Completed
30 enrolled
Sarcoma

AIDS-related Kaposi sarcoma, Sarcoma, Kaposi

NCT00027677 2012-07-24

Halofuginone Hydrobromide in Treating Patients With Progressive Advanced Solid Tumors

European Organisation for Research and Treatment of Cancer - EORTC

Phase 1 Completed
25 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡